RxDoctor Payments Data

Christina Kraus, NP

Nurse Practitioner · Carbondale, ILNPI 1750504023

Payments from drug & device makers

$613in general payments, 2019–2025

Across 23 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$140
  • E.r. Squibb & Sons, L.L.C.$113
  • Kestra Medical Technology Services, Inc.$78
  • Novartis$53
  • Abbott$49
  • Esperion Therapeutics, Inc.$35
  • plus $146 from 7 others

What the payments were for

  • Food & beverage$613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$613 in reported general payments places this provider in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$76,124
Medicare patients
515
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$183,261
EntrestoSacubitril/Valsartan31$28,213
XareltoRivaroxaban30$26,379
Ranolazine ErRanolazine40$3,119
Metoprolol Succinate237$2,938
Nifedipine ErNifedipine43$1,641
Atorvastatin Calcium142$1,210
Carvedilol87$841
Rosuvastatin Calcium40$750
Lisinopril81$718
Nitroglycerin PatchNitroglycerin15$654
ClopidogrelClopidogrel Bisulfate55$620
Ezetimibe34$577
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$504
Isosorbide Mononitrate ErIsosorbide Mononitrate47$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$53$28,21331 claims
Johnson & JohnsonXarelto$15$26,37930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Carbondale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →